Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin

P. Kaspar, M. Zikova, P. Bartunek, J. Sterba, H. Strnad, L. Kren, R. Sedlacek,

. 2015 ; 5 (-) : 15090. [pub] 20151014

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028100

The transcription factor c-Myb is required for modulation of progenitor cells in several tissues, including skeletal muscle and its upregulation is observed in many human malignancies. Rhabdomyosarcomas (RMS) are a heterogeneous group of mesodermal tumors with features of developing skeletal muscle. Several miRNAs are downregulated in RMS, including miR-150, a negative regulator of c-Myb expression. Using the C2C12 myoblast cell line, a cellular model of skeletal muscle differentiation, we showed that miR-150 controls c-Myb expression mainly at the level of translation. We hypothesized that a similar mechanism of c-Myb regulation operates in RMS tumors. We examined expression of c-Myb by immunohistochemistry and revealed c-Myb positivity in alveolar and embryonal tumors, the two most common subgroups of RMS. Furthermore, we showed direct correlation between c-Myb production and myogenin expression. Interestingly, high myogenin levels indicate poor prognosis in RMS patients. c-Myb could, therefore, contribute to the tumor phenotype by executing its inhibitory role in skeletal muscle differentiation. We also showed that c-Myb protein is abundant in migratory C2C12 myoblasts and its ectopic expression potentiates cell motility. In summary, our results implicate that metastatic properties of some RMS subtypes might be linked to c-Myb function.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028100
003      
CZ-PrNML
005      
20161005131438.0
007      
ta
008      
161005s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/srep15090 $2 doi
024    7_
$a 10.1038/srep15090 $2 doi
035    __
$a (PubMed)26462877
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kaspar, Petr $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
245    14
$a The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin / $c P. Kaspar, M. Zikova, P. Bartunek, J. Sterba, H. Strnad, L. Kren, R. Sedlacek,
520    9_
$a The transcription factor c-Myb is required for modulation of progenitor cells in several tissues, including skeletal muscle and its upregulation is observed in many human malignancies. Rhabdomyosarcomas (RMS) are a heterogeneous group of mesodermal tumors with features of developing skeletal muscle. Several miRNAs are downregulated in RMS, including miR-150, a negative regulator of c-Myb expression. Using the C2C12 myoblast cell line, a cellular model of skeletal muscle differentiation, we showed that miR-150 controls c-Myb expression mainly at the level of translation. We hypothesized that a similar mechanism of c-Myb regulation operates in RMS tumors. We examined expression of c-Myb by immunohistochemistry and revealed c-Myb positivity in alveolar and embryonal tumors, the two most common subgroups of RMS. Furthermore, we showed direct correlation between c-Myb production and myogenin expression. Interestingly, high myogenin levels indicate poor prognosis in RMS patients. c-Myb could, therefore, contribute to the tumor phenotype by executing its inhibitory role in skeletal muscle differentiation. We also showed that c-Myb protein is abundant in migratory C2C12 myoblasts and its ectopic expression potentiates cell motility. In summary, our results implicate that metastatic properties of some RMS subtypes might be linked to c-Myb function.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myogenin $7 D018008
650    _2
$a protoonkogenní proteiny c-myb $x metabolismus $7 D020598
650    _2
$a rhabdomyosarkom $x metabolismus $x patologie $x sekundární $7 D012208
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zikova, Martina $u Laboratory of Cell Differentiation, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Bartunek, Petr $u Laboratory of Cell Differentiation, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Sterba, Jaroslav $u The University Hospital Brno, Brno, Czech Republic.
700    1_
$a Strnad, Hynek $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Kren, Leos $u The University Hospital Brno, Brno, Czech Republic.
700    1_
$a Sedlacek, Radislav $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 5, č. - (2015), s. 15090
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26462877 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161005131826 $b ABA008
999    __
$a ok $b bmc $g 1166414 $s 952730
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 5 $c - $d 15090 $e 20151014 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace